SURGISTAR acquired by HALMA
Context
Halma, a global leader in healthcare technology, has completed the acquisition of 100% of Surgistar’s share capital, further strengthening its ophthalmic instrument capabilities within its Healthcare division. Through this transaction, Halma aims to bring the production of high-precision disposables in-house, helping to better secure its supply chain against external volatility. From an industrial standpoint, the deal is driven by the combination of Surgistar’s automated sharpening technologies with Halma’s clinical and commercial reach, ensuring consistently high-quality cutting performance for demanding ophthalmic teams. Rather than simply expanding capacity, the acquisition is expected to unlock meaningful product synergies by integrating a specialized portfolio of blades and cannulas into Halma’s global direct sales network.
The acquisition of Surgistar is part of the growth strategy of Halma, which already has several external growth operations under its belt, notably Safetec in 2026.
SURGISTAR, which reported an EBITDA margin of in 2026, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Surgistar is a specialized technology organization dedicated to the design and manufacturing of high-precision surgical instruments for ophthalmic procedures. The entity’s business model is centered on a proprietary framework of single-use blades, cannulas, and trephines, utilizing highly automated manufacturing processes to ensure consistent quality and sharpness. Its value proposition is anchored in technical operational depth, providing critical tools for micro-surgical interventions in vision care. Strategically, the firm focuses on the development of differentiated surgical solutions that meet the stringent requirements of surgeons globally. By maintaining a niche leadership position in the precision instrument market, the organization ensures a mission-critical role in the healthcare supply chain. The entity prioritizes manufacturing excellence and technological agility to facilitate the structural improvement of patient outcomes in surgical settings.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (GBP)
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 06/2026 | BRIDGEPOINT | OBAGI MEDICAL | UNITED STATES | Generics / Labs |
| 05/2026 | STRYKER | AMPLITUDE VASCULAR SYSTEMS | UNITED STATES | Medical Devices |
| 04/2026 | REVENIO GROUP CORPORATION | VISIONIX INTERNATIONAL | FRANCE | Diagnostic Equipment |
| 04/2026 | OURY MEDICAL | CÉFIMÉCA | FRANCE | Implants & Prosthetics |
| 04/2026 | ASTORG | THERMO FISHER MICROBIOLOGY | UNITED STATES | Diagnostic Equipment |
| 04/2026 | FOR TALENTS / UI INVESTISSEMENT / GENEO | NEFTYS PHARMA | FRANCE | Animal Health |
| 04/2026 | RANTUM CAPITAL | TONTARRA MEDIZINTECHNIK | GERMANY | Medical Devices |
| 04/2026 | FINE FOODS & PHARMACEUTICALS | SOFAR | ITALY | CDMO |
| 04/2026 | Gilead Sciences | Arcellx | UNITED STATES | R&D Biotech |
| 04/2026 | AMERICAN INDUSTRIAL PARTNERS AIP | AVANOS MEDICAL | UNITED STATES | Medical Consumables |
REFERENCES
Valuation range: EV 50M - 150M GBP
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of SURGISTAR by HALMA are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Target: surgistar
Acquirer: halma